中药联合放化疗治疗中期非小细胞肺癌的临床疗效

Clinical Efficacy of Traditional Chinese Medicine Combined with Radiotherapy and Chemotherapy in the treatment of Non-small Cell Lung Cancer

目的:探讨中药联合放化疗手段治疗中期非小细胞肺癌患者的临床效果。方法:选取2012年1月-2014年1月陕西中医药大学附属医院肿瘤科、肿瘤科和呼吸科收治的非小细胞肺癌患者80例作为本研究的研究对象,按照入院顺序将其随机分为对照组和治疗组。对照组39例给予常规放化疗治疗,治疗组41例在对照组的基础上给予参芪五味子片进行治疗。比较两组患者的近期疗效、治疗前后卡氏(KPS)评分情况、T淋巴细胞亚群的变化情况及不良反应的发生情况。结果:治疗后,治疗组的总体有效率为39.02%,与对照组(28.20%)比较差异无统计学意义(P>0.05)。治疗组患者治疗后的KPS评分改善率为70.70%,明显高于对照组(42.00%,P<0.05)。两组患者治疗后的CD3^+、CD4^+、CD4^+/CD8^+水平均较治疗前显著升高、CD8^+水平较治疗前明显降低,且治疗组CD3^+、CD4^+、CD4^+/CD8^+水平显著高于对照组,而CD8^+水平明显低于对照组(P<0.05)。治疗组的各不良反应发生率均显著低于对照组(P<0.05)。结论:中药联合放化疗治疗中期非小细胞肺癌虽不能显著提高临床效果,但可有效缓解放化疗所致的不良反应,提高患者免疫功能,改善患者的生活质量。

Objective: To explore the clinical effect of traditional Chinese medicine combined with radiotherapy and chemotherapy in the treatment of patients with non-small cell lung cancer at the early and middle stage. Methods: 80 patients with non-small cell lung cancer admitted to the Department of Oncology, Oncology and Respiratory Diseases of the Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine from January 2012 to January 2014 were selected as the study subjects. According to the admission order,they were randomly divided into the control group and the treatment group. 39 patients in the control group were treated with conventional radiotherapy and chemotherapy, 41 patients in the treatment group were treated with Shenqi Schisandra tablets on the basis of control group. The short-term efficacy, changes of Kaposr(KPS) score, T lymphocyte subsets before and after treatment and the occurrence of adverse reactions were compared between two groups. Results: After treatment, the overall effective rate of treatment group was 39.02%,and there was no significant difference compared with the control group(28.20%)(P>0.05). The improvement rate of KPS score after treatment in the treatment group was 70.70%, which was significantly higher than that in the control group(42.00%, P<0.05). The levels of CD3^+, CD4^+, CD4^+/CD8^+ in the two groups were significantly higher than those before treatment, and the level of CD8+was significantly lower than that before treatment.The levels of CD3^+, CD4^+ and CD4^+/CD8^+ in the treatment group were significantly higher than those in the control group, while the level of CD8+was significantly lower than that in the control group(P<0.05). The incidence of adverse reactions in the treatment group was significantly lower than that in the control group(P<0.05). Conclusion: Although traditional Chinese medicine combined with radiotherapy and chemotherapy for the treatment of metaphase non-small cell lung cancer can not significantly improve the clinical effect, it can effectively alleviate the adverse reactions caused by radiotherapy and chemotherapy, improve the patients’ immune function and the quality of life.